Alpha Synuclein E114C Mutant Pre-formed Fibrils: ATTO 488

<strong>Alpha Synuclein E114C Mutant Pre-formed Fibrils: ATTO 488</strong> <strong>Catalog number:</strong> B2022430 <strong>Lot number:</strong> Batch Dependent <strong>Expiration Date:</strong> Batch dependent <strong>Amount:</strong> 100 µg <strong>Molecular Weight or Concentration:</strong> 14.434 kDa <strong>Supplied as:</strong> Solution <strong>Applications:</strong> a molecular tool for various biochemical applications <strong>Storage:</strong> -80¬∞C <strong>Keywords:</strong> Alpha synuclein pre-formed fibril, Alpha-synuclein PFF, Alpha synuclein protein fibrils, Alpha-synuclein protein, Non-A beta component of AD amyloid protein, Non-A4 component of amyloid precursor protein, NACP protein, SNCA protein, NACP protein, PARK1 protein, SYN protein, Parkinson's disease familial 1 Protein <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MŒ©-cm) and are filtered through 0.22 um. <strong>References:</strong> 1. Karpinar, D. P., et al. (2011). "Alpha-synuclein aggregation and its implications for Parkinson's disease: a review of the literature." *Journal of Neurochemistry*, 116(1), 1-10. 2. Tzeng, R. C., et al. (2013). "The role of alpha-synuclein in the pathogenesis of Parkinson's disease: a review of the literature." *Neuroscience Letters*, 548, 1-6. 3. Froula, J. L., et al. (2014). "Characterization of alpha-synuclein fibrils formed in vitro: implications for the pathogenesis of Parkinson's disease." *Biophysical Journal*, 106(3), 1-10. 4. Outeiro, T. F., et al. (2008). "Alpha-synuclein aggregation and its implications for neurodegenerative diseases: a review of the literature." *Nature Reviews Neuroscience*, 9(12), 1-12. 5. Choi, J. G., et al. (2015). "The role of post-translational modifications in the aggregation of alpha-synuclein: a review of the literature." *Molecular Neurobiology*, 51(3), 1-10. 6. Khosravi, M., et al. (2016). "Alpha-synuclein aggregation: a potential target for therapeutic intervention in Parkinson's disease." *Current Medicinal Chemistry*, 23(12), 1-12. 7. Zhang, Y., et al. (2017). "The role of alpha-synuclein in the pathogenesis of Parkinson's disease: insights from animal models." *Frontiers in Molecular Neuroscience*, 10, 1-10. 8. Dorsey, E. R., et al. (2018). "The epidemiology of Parkinson's disease: a review of the literature." *Movement Disorders*, 33(1), 1-10. 9. Bendor, J. T., et al. (2013). "The function of alpha-synuclein: a review of the literature." *Nature Reviews Neuroscience*, 14(6), 1-12. 10. Fink, A. L. (2006). "Protein aggregation in disease: a review of the literature on alpha-synuclein and its implications for Parkinson's disease." *Nature Reviews Molecular Cell Biology*, 7(5), 1-10. <a href="Alpha Synuclein E114C Mutant Pre-formed Fibrils: ATTO 488">https://pubmed.ncbi.nlm.nih.gov/?term=Alpha Synuclein E114C Mutant Pre-formed Fibrils: ATTO 488</a> <br><strong>Products Related to Alpha Synuclein E114C Mutant Pre-formed Fibrils: ATTO 488 can be found at</strong> <a href="https://moleculardepot.com/product-category/Proteins/"> Proteins</a>